iBio Reports Fiscal Second Quarter 2025 Financial Results

Core Insights - iBio, Inc. reported financial results for the second quarter ended December 31, 2024, highlighting advancements in its preclinical pipeline and corporate governance [1][4]. Corporate Developments - The company strengthened its leadership with key Board appointments, emphasizing its commitment to innovation and execution in developing next-generation therapeutics [2]. - iBio made significant progress in its preclinical pipeline, including the in-licensing of IBIO-600, a novel Activin E antibody discovery, and the initiation of a bispecific antibody program targeting myostatin/activin A [2][5]. Financial Performance - Revenue for the quarter was reported at 0.2 million, attributed to services provided to a collaborative partner [5]. - Research and Development (R&D) and General & Administrative (G&A) expenses totaled approximately 4.6 million, reflecting a slight increase of about 3% compared to the same period in fiscal 2024 [5]. - The net loss from continuing operations for the quarter was approximately $4.4 million, or$0.48 per share, compared to a net loss of approximately $4.5 million, or$2.42 per share, in the same period of fiscal 2024 [5]. Cash Position - As of December 31, 2024, the company reported cash, cash equivalents, and restricted cash of approximately $7.2 million, which includes$0.2 million of restricted cash [5].